The disclosure relates to 2-phenyl-4-cyclopropyl-pyrimidine derivatives of formula (I), wherein R1 represents phenyl optionally substituted once by halogen, methyl, methoxy, trifluoromethyl or trifluoromethoxy and R2 represents hydrogen, hydroxymethyl or alkoxymethyl. These compounds of formula (I) are suitable for use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.
